ST12
MCID: SPP011
MIFTS: 61

Suppression of Tumorigenicity 12 (ST12)

Categories: Cancer diseases, Reproductive diseases

Aliases & Classifications for Suppression of Tumorigenicity 12

MalaCards integrated aliases for Suppression of Tumorigenicity 12:

Name: Suppression of Tumorigenicity 12 57
Prostate Adenocarcinoma 57 12 13 15 17
Adenocarcinoma of Prostate 6 70
Prostate Adenocarcinoma 1; Pac1 57
Prostate Adenocarcinoma 1 57
St12 57
Pac1 57

Classifications:



External Ids:

Disease Ontology 12 DOID:2526
OMIM® 57 601188
NCIt 50 C2919
SNOMED-CT 67 399490008
UMLS 70 C0007112

Summaries for Suppression of Tumorigenicity 12

Disease Ontology : 12 A prostate carcinoma that derives from epithelial cells of glandular origin.

MalaCards based summary : Suppression of Tumorigenicity 12, also known as prostate adenocarcinoma, is related to adenocarcinoma and small cell carcinoma. An important gene associated with Suppression of Tumorigenicity 12 is KLF6 (Kruppel Like Factor 6), and among its related pathways/superpathways are Signaling by GPCR and Innate Immune System. The drugs Prilocaine and Lidocaine have been mentioned in the context of this disorder. Affiliated tissues include prostate, bone and breast, and related phenotypes are Decreased viability and Decreased viability

More information from OMIM: 601188

Related Diseases for Suppression of Tumorigenicity 12

Diseases related to Suppression of Tumorigenicity 12 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 577)
# Related Disease Score Top Affiliating Genes
1 adenocarcinoma 31.9 TP53 SMAD4 PTEN PIK3CA MAP2K1 HRAS
2 small cell carcinoma 30.9 TP53 PTEN ERBB2 CDKN2A
3 meningioma, familial 30.8 TP53 PTEN PIK3CA H2AC18 CDKN2A AKT1
4 transitional cell carcinoma 30.8 TP53 PTEN HRAS ERBB2 CDKN2A BRAF
5 mucinous adenocarcinoma 30.6 TP53 ERBB2 CDKN2A
6 adenosquamous carcinoma 30.6 TP53 SMAD4 PTEN PIK3CA CDKN2A
7 mantle cell lymphoma 30.5 XPO1 TP53 PTEN PIK3CA CTNNB1 CDKN2A
8 adenoma 30.5 TP53 SMAD4 PIK3CA CTNNB1 CDKN2A BRAF
9 signet ring cell adenocarcinoma 30.5 TP53 HRAS ERBB2 CTNNB1
10 neuroblastoma 30.5 TP53 PTEN PIK3CA MAP2K1 HRAS ERBB2
11 villous adenoma 30.5 TP53 HRAS BRAF
12 renal cell carcinoma, nonpapillary 30.5 TP53 PTEN PIK3CA HRAS H2AC18 BRAF
13 prostate squamous cell carcinoma 30.5 TP53 PIK3CA MAP2K1 LRRC56 HRAS CDKN2A
14 appendix adenocarcinoma 30.4 SMAD4 HRAS
15 neurofibroma 30.4 TP53 PTEN ERBB2 CDKN2A
16 anal squamous cell carcinoma 30.4 TP53 PIK3CA CDKN2A AKT1
17 pancreatic ductal carcinoma 30.4 TP53 SMAD4 ERBB2 CDKN2A
18 thyroid tumor 30.4 PTEN BRAF
19 connective tissue benign neoplasm 30.4 TP53 H2AC18 CTNNB1
20 small cell cancer of the lung 30.4 TP53 PTEN PIK3CA CDKN2A AKT1
21 retinitis pigmentosa 11 30.3 TP53 PTEN H2AC18 CDKN2A
22 penile cancer 30.3 TP53 PTEN PIK3CA HRAS CDKN2A
23 carcinosarcoma 30.3 TP53 PTEN PPP2R1A PIK3CA HRAS ERBB2
24 familial adenomatous polyposis 30.3 TP53 SMAD4 HRAS CTNNB1
25 liposarcoma 30.3 TP53 PTEN PIK3CA CTNNB1 CDKN2A
26 squamous cell carcinoma 30.3 TP53 SMAD4 PTEN PIK3CA MAP2K1 HRAS
27 prostate cancer 30.3 TP53 SPOP SMAD4 PTEN PIK3CA MAP2K1
28 leukemia, chronic lymphocytic 30.3 XPO1 TP53 PTEN LRRC56 HRAS H2AC18
29 myeloma, multiple 30.3 TP53 PTEN PIK3CA LRRC56 IDH1 HRAS
30 glioma 30.3 TP53 PTEN PIK3CA IDH1 ERBB2 CDKN2A
31 sarcoma 30.3 TP53 PIK3CA HRAS CTNNB1 BRAF AKT1
32 cystadenocarcinoma 30.3 TP53 PPP2R1A PIK3CA HRAS ERBB2 BRAF
33 gastrointestinal stromal tumor 30.2 TP53 PTEN ERBB2 CDKN2A BRAF AKT1
34 melanoma 30.2 TP53 PTEN PIK3CA MAP2K1 LRRC56 IDH1
35 bladder cancer 30.2 TP53 PTEN PIK3CA MAP2K1 LRRC56 HRAS
36 plasma cell neoplasm 30.2 TP53 PIK3CA LRRC56 IDH1 HRAS BRAF
37 peripheral nervous system disease 30.1 TP53 PTEN HRAS H2AC18 ERBB2 CTNNB1
38 myelodysplastic syndrome 30.1 TP53 PTEN LRRC56 IDH1 HRAS ERBB2
39 medulloblastoma 30.0 TP53 PTEN PIK3CA MAP2K1 IDH1 HRAS
40 glioblastoma 30.0 TP53 PTEN PIK3CA LRRC56 IDH1 HRAS
41 endometrial cancer 29.9 TP53 SMAD4 PTEN PPP2R1A PIK3CA HRAS
42 bladder urothelial carcinoma 29.9 TP53 PTEN PIK3CA MAP2K1 LRRC56 IDH1
43 comedo carcinoma 29.8 TP53 ERBB2
44 melanoma, uveal 29.8 TP53 SMAD4 PTEN PIK3CA MAP2K1 HRAS
45 leukemia, acute myeloid 29.7 XPO1 TP53 PTEN PIK3CA MAP2K1 LRRC56
46 skin melanoma 29.6 TP53 PTEN PIK3CA MAP2K1 LRRC56 IDH1
47 squamous cell carcinoma, head and neck 29.6 TP53 SMAD4 PTEN PPP2R1A PIK3CA MAP2K1
48 lung cancer 29.5 TP53 SMAD4 PTEN PPP2R1A PIK3CA MAP2K1
49 gastric adenocarcinoma 29.5 TP53 SMAD4 PTEN PPP2R1A PIK3CA MED12
50 prostate colloid adenocarcinoma 11.4

Graphical network of the top 20 diseases related to Suppression of Tumorigenicity 12:



Diseases related to Suppression of Tumorigenicity 12

Symptoms & Phenotypes for Suppression of Tumorigenicity 12

Clinical features from OMIM®:

601188 (Updated 20-May-2021)

GenomeRNAi Phenotypes related to Suppression of Tumorigenicity 12 according to GeneCards Suite gene sharing:

26 (show all 15)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 10.25 BRAF PIK3CA HRAS
2 Decreased viability GR00055-A-2 10.25 BRAF PIK3CA HRAS
3 Decreased viability GR00107-A-1 10.25 MAP2K1
4 Decreased viability GR00221-A-1 10.25 AKT1 CDKN2A PIK3CA HRAS
5 Decreased viability GR00221-A-2 10.25 AKT1 PIK3CA HRAS
6 Decreased viability GR00221-A-3 10.25 AKT1 CDKN2A ERBB2 HRAS MAP2K1
7 Decreased viability GR00221-A-4 10.25 AKT1 BRAF CDKN2A ERBB2 PIK3CA
8 Decreased viability GR00249-S 10.25 AKT1 BRAF
9 Decreased viability GR00301-A 10.25 BRAF
10 Decreased viability GR00381-A-1 10.25 BRAF
11 Decreased viability GR00402-S-2 10.25 PIK3CA
12 Decreased cell migration GR00055-A-1 9.56 AKT1
13 Decreased cell migration GR00055-A-3 9.56 BRAF HRAS PIK3CA
14 Decreased sensitivity to paclitaxel GR00112-A-0 8.85 PTEN
15 Increased focal adhesion (FA) area, decreased number of small and round FAs, increased peripheral FA formation, increased cell spreading GR00210-A 8.32 CTNNB1

MGI Mouse Phenotypes related to Suppression of Tumorigenicity 12:

46 (show all 19)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.46 AKT1 BRAF CDKN2A CTNNB1 ERBB2 HRAS
2 growth/size/body region MP:0005378 10.45 AKT1 BRAF CDKN2A CTNNB1 ERBB2 HRAS
3 embryo MP:0005380 10.42 AKT1 BRAF CDKN2A CNOT9 CTNNB1 ERBB2
4 homeostasis/metabolism MP:0005376 10.41 AKT1 BRAF CDKN2A CNOT9 CTNNB1 ERBB2
5 cellular MP:0005384 10.39 AKT1 BRAF CDKN2A CTNNB1 ERBB2 KLF6
6 mortality/aging MP:0010768 10.39 AKT1 BRAF CDKN2A CTNNB1 ERBB2 HRAS
7 endocrine/exocrine gland MP:0005379 10.35 AKT1 BRAF CDKN2A CTNNB1 ERBB2 HRAS
8 integument MP:0010771 10.31 AKT1 BRAF CDKN2A CTNNB1 ERBB2 HRAS
9 digestive/alimentary MP:0005381 10.21 BRAF CDKN2A CTNNB1 ERBB2 HRAS MAP2K1
10 craniofacial MP:0005382 10.17 BRAF CTNNB1 ERBB2 HRAS MAP2K1 MED12
11 nervous system MP:0003631 10.17 AKT1 BRAF CDKN2A CNOT9 CTNNB1 ERBB2
12 neoplasm MP:0002006 10.15 AKT1 BRAF CDKN2A CTNNB1 ERBB2 HRAS
13 liver/biliary system MP:0005370 10.11 AKT1 BRAF CDKN2A CTNNB1 KLF6 PTEN
14 muscle MP:0005369 10.1 AKT1 BRAF CDKN2A CTNNB1 ERBB2 HRAS
15 limbs/digits/tail MP:0005371 10.08 BRAF CTNNB1 ERBB2 MED12 PTEN SMAD4
16 normal MP:0002873 10 AKT1 BRAF CTNNB1 ERBB2 HRAS MAP2K1
17 reproductive system MP:0005389 9.93 AKT1 BRAF CDKN2A CTNNB1 ERBB2 KLF6
18 respiratory system MP:0005388 9.61 AKT1 BRAF CDKN2A CTNNB1 ERBB2 HRAS
19 skeleton MP:0005390 9.47 AKT1 BRAF CDKN2A CTNNB1 ERBB2 HRAS

Drugs & Therapeutics for Suppression of Tumorigenicity 12

Drugs for Suppression of Tumorigenicity 12 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 190)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Prilocaine Approved Phase 4 721-50-6 4906
2
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
3
Fesoterodine Approved Phase 4 286930-03-8, 286930-02-7 6918558
4 Anesthetics Phase 4
5 Sodium Channel Blockers Phase 4
6 Anti-Arrhythmia Agents Phase 4
7 Diuretics, Potassium Sparing Phase 4
8 Anesthetics, Local Phase 4
9 Cholinergic Agents Phase 4
10 Cholinergic Antagonists Phase 4
11 Muscarinic Antagonists Phase 4
12
Methyltestosterone Approved Phase 3 58-18-4 6010
13
Testosterone undecanoate Approved, Investigational Phase 3 5949-44-0
14
Testosterone enanthate Approved Phase 3 315-37-7 9416
15
Testosterone Approved, Investigational Phase 3 58-22-0 6013
16
Medroxyprogesterone acetate Approved, Investigational Phase 3 71-58-9
17
Norepinephrine Approved Phase 3 51-41-2 439260
18
Cyproterone Acetate Approved, Investigational Phase 3 427-51-0
19
Leuprolide Approved, Investigational Phase 2, Phase 3 53714-56-0 3911 657181
20
Salicylic acid Approved, Investigational, Vet_approved Phase 2, Phase 3 69-72-7 338
21
Flutamide Approved, Investigational Phase 2, Phase 3 13311-84-7 3397
22
Nilutamide Approved, Investigational Phase 2, Phase 3 63612-50-0 4493
23
Bicalutamide Approved Phase 3 90357-06-5 56069 2375
24
Goserelin Approved Phase 3 65807-02-5 47725 5311128
25
Vitamin C Approved, Nutraceutical Phase 3 50-81-7 5785 54670067
26
Lysine Approved, Nutraceutical Phase 2, Phase 3 56-87-1 5962
27 Bombesin Investigational Phase 2, Phase 3 31362-50-2
28 Prolactin Release-Inhibiting Factors Phase 3
29 Trace Elements Phase 3
30 Nutrients Phase 3
31 Micronutrients Phase 3
32 Antioxidants Phase 3
33 Anabolic Agents Phase 3
34 Vitamins Phase 3
35 Testosterone 17 beta-cypionate Phase 3
36 Estrogens, Conjugated (USP) Phase 3
37 Antimetabolites Phase 3
38 Hypolipidemic Agents Phase 3
39 Nootropic Agents Phase 3
40 Lipid Regulating Agents Phase 3
41 Contraceptive Agents Phase 3
42 Vaccines Phase 3
43 Venlafaxine Hydrochloride Phase 3
44
Medroxyprogesterone Phase 3 520-85-4 10631
45 Contraceptives, Oral Phase 3
46 Serotonin and Noradrenaline Reuptake Inhibitors Phase 3
47 Contraceptive Agents, Male Phase 3
48
Cyproterone Phase 3 2098-66-0 5284537
49 Neurotransmitter Agents Phase 2, Phase 3
50 gastrin-releasing peptide Phase 2, Phase 3

Interventional clinical trials:

(show top 50) (show all 154)
# Name Status NCT ID Phase Drugs
1 Impact of Local Anesthesia Type on Cancer Detection Rate in Transrectal Ultrasound Guided Prostate Biopsy Completed NCT02025361 Phase 4 intrarectal lidocaine gel;periprostatic nerve blockade
2 A Phase IV, Randomized, Double-Blind, Placebo-Controlled, Single-Center Study of the Effects of Fesoterodine in Men at High Risk for Overactive Bladder/Detrusor Overactivity Post Robotic-Assisted Laparoscopic Prostatectomy ) Completed NCT01661166 Phase 4 Fesoterodine;Placebo oral tablet
3 Comparison of High-dose- Versus Low-dose-rate Brachytherapy as Monotherapy in the Treatment of Early, Organ Confined Prostate Cancer. Unknown status NCT02258087 Phase 2, Phase 3
4 Staging of Untreated Patients With Very High-risk and High-risk Prostate Carcinoma Utilizing Hybrid C11-choline PET/MR and Pelvic Multiparametric MRI for Personalized Precise Treatment: a Pilot Study Completed NCT03404648 Phase 3 C-11 choline PET tracer;Gadobutrol
5 Phase III Multicenter Randomized Trial of Adjuvant Androgen Deprivation in Combination With Three-dimensional Conformal Radiotherapy Doses in High and Intermediate Risk Localized Prostate Cancer. Completed NCT02175212 Phase 3 Short term androgen deprivation;Long term androgen deprivation
6 Efficacy and Tolerance of Cyproterone Acetate Versus Medroxyprogesterone Acetate Versus Venlafaxine LP in the Treatment of Hot Flushes Caused by Leuprorelin 11.25 mg in Patients Treated for a Prostate Adenocarcinoma Completed NCT01011751 Phase 3 Cyproterone acetate;Medroxyprogesterone acetate;Venlafaxine;Leuprorelin;Flutamide;Placebo
7 A Phase 3, Multi-Center, Open-Label, Trial to Evaluate the Efficacy, Safety and Pharmacokinetics of Two 6-Month Leuprolide Formulations, in Subjects With Prostatic Adenocarcinoma Completed NCT00626431 Phase 3 Leuprolide acetate - Formulation A;Leuprolide acetate - Formulation B
8 A Randomized, Double Blind, Placebo Controlled Phase 3 Trial of Immunotherapy With Autologous Antigen Presenting Cells Loading With PA2024 (Provenge(R), APC8015) in Men With Metastatic Androgen Independent Prostatic Adenocarcinoma Completed NCT00065442 Phase 3
9 A Phase III Randomized Pilot Study of Low Dose Rate Compared to High Dose Rate Prostate Brachytherapy for Favourable Risk and Low Tier Intermediate Risk Prostate Cancer Recruiting NCT02692105 Phase 3
10 A Randomized Phase III, Factorial Design, of Cabazitaxel and Pelvic Radiotherapy in Patients With Localized Prostate Cancer and High-risk Features of Relapse Recruiting NCT01952223 Phase 3 Cabazitaxel
11 68Ga-RM2 PET/MRI in the Evaluation of Patients With Biochemical Recurrence of Prostate Cancer and Non-contributory CT Scans Recruiting NCT02624518 Phase 2, Phase 3 Gallium Ga 68-labeled GRPR Antagonist BAY86-7548
12 Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer Recruiting NCT03367702 Phase 3
13 Phase II-III Trial of Adjuvant Radiotherapy Following Radical Prostatectomy With or Without Adjuvant Docetaxel Recruiting NCT03070886 Phase 2, Phase 3 Bicalutamide;Docetaxel;Flutamide;Goserelin Acetate;Leuprolide Acetate;Nilutamide
14 68-Ga PSMA 11 PET/CT for Detection of Recurrent Prostate Cancer After Initial Therapy in Patients With Elevated PSA Active, not recruiting NCT02673151 Phase 2, Phase 3 Gallium Ga 68-labeled PSMA-11
15 68Ga-PSMA-11 PET/MRI for Detection of Regional Nodal and Distant Metastases in Patients With Intermediate and High-Risk Prostate Cancer Active, not recruiting NCT02678351 Phase 2, Phase 3 gallium Ga 68-PSMA-11
16 PALS: Prostate Cancer Active Lifestyle Study Active, not recruiting NCT02454517 Phase 3
17 A Randomized Phase III Trial of Hypofractionated Post-prostatectomy Radiation Therapy (HYPORT) Versus Conventional Post-prostatectomy Radiation Therapy (COPORT) Active, not recruiting NCT03274687 Phase 3
18 Randomized, Multicentre, Phase III Study in Patients With Intermediate-risk T1 T2 Prostate Adenocarcinomas, to Verify the Role of Six Months of Total Androgen Blockade for Two Dosage Levels of Prostate Radiation Therapy (70 Gy and 76 Gy) Versus Prostate Radiation Therapy Alone at 76 Gy Active, not recruiting NCT00223145 Phase 3 Androgen blockade
19 Moderate Hypofractionated Radiotherapy (62 Gy in 20 Fractions of 3.1 Gy) Versus Stereotactic Radiotherapy (37.5 Gy in 5 Fractions of 7.5 Gy) With Hyaluronic Acid Injection Between the Prostate and the Rectum for Prostate Cancer of Low- to Intermediate Risk; RPAH2 Unknown status NCT02361515 Phase 2
20 Neoadjuvant Androgen Depletion in Combination With Vorinostat Followed by Radical Prostatectomy for Localized Prostate Cancer: Total Androgen-Receptor Gene Expression Targeted Therapy (TARGET) Completed NCT00589472 Phase 2 Bicalutamide;Goserelin Acetate;Leuprolide Acetate;Vorinostat
21 A Randomized Phase II Study of Androgen Deprivation Combined With IMC-A12 Versus Androgen Deprivation Alone for Patients With New Hormone Sensitive Metastatic Prostate Cancer Completed NCT01120236 Phase 2 Bicalutamide;Goserelin Acetate;Leuprolide Acetate
22 A Phase II Neoadjuvant Study of Apalutamide, Abiraterone Acetate, Prednisone, Degarelix and Indomethacin in Men With Localized Prostate Cancer Pre-Prostatectomy Completed NCT02849990 Phase 2 Abiraterone Acetate;Apalutamide;Degarelix;Indomethacin;Prednisone
23 Phase IIA, Randomized Placebo-Controlled Trial of Single High Dose Cholecalciferol and Daily Genistein (G-2535) Versus Placebo in Men With Early Stage Prostate Cancer Undergoing Prostatectomy Completed NCT01325311 Phase 2 Cholecalciferol;Genistein
24 Evaluation of Hypoxia by PET With 18-FluoroMisonidazole During Radiation Therapy of Prostate Cancer Completed NCT01898065 Phase 2 18-F-MISO
25 A Phase II Pilot Study of Estramustine, Docetaxel, and Carboplatin for Patients With Hormone Refractory Prostate Cancer Progressing After Mitoxantrone-Based Chemotherapy. Completed NCT00183924 Phase 2 Estramustine;Docetaxel;Carboplatin
26 A Phase II Immunotherapeutic Trial: Combination Androgen Ablative Therapy and CTLA-4 Blockade as a Treatment for Advanced Prostate Cancer Completed NCT00170157 Phase 2 Bicalutamide;Flutamide;Goserelin Acetate;Ipilimumab;Leuprolide Acetate
27 Hedgehog Inhibition as a Non-Castrating Approach to Hormone Sensitive Prostate Cancer: A Phase II Study of Itraconazole in Biochemical Relapse Completed NCT01787331 Phase 2 Itraconazole
28 C11-Sodium Acetate PET/CT Imaging for Metastatic Disease in Intermediate-to-high Risk Prostate Adenocarcinoma Completed NCT01530269 Phase 2 C11-Sodium Acetate
29 A Trial Of Neoadjuvant Androgen Supression And Dose Escalation Transperineal Ultrasound-Guided Brachytherapy For Locally Recurrent Prostate Adenocarcinoma Following External Beam Radiotherapy Completed NCT00032006 Phase 2
30 A Phase II Open Label Trial of Amifostine Plus Fractionated Radiotherapy for Primary Prostate Adenocarcinoma (T1a-T3b, NoMo, PSA>10 ng/ml) to Estimate Acute Grade 2 Genitourinary and Gastrointestinal Toxicity Completed NCT00003307 Phase 2 amifostine trihydrate
31 A Phase I/II Study Evaluating the Safety and Efficacy of Vaccination With Autologous Dendritic Cells Loaded With Tn-MUC1 Peptide in Patients With Non-Metastatic Androgen Independent Prostatic Adenocarcinoma. Completed NCT00852007 Phase 1, Phase 2
32 Phase II Trial of Bicalutamide and RAD001 in Patients With Hormone-Independent Prostatic Adenocarcinoma (HIPC) After the First-Line Androgen Deprivation Therapy Completed NCT00814788 Phase 2 Bicalutamide;Everolimus
33 The Impact of Dose Escalation Using Gold Markers in Image Guided Volumetric Modulated Arc Radiotherapy to the Focal Lesion Micro Boost of Localized Prostate Cancer Completed NCT03384199 Phase 2
34 WALNUTS for POWER: Polyphenols, Omega-3 Fatty Acids, Weight Loss, and EneRgy Recruiting NCT03824652 Phase 2
35 PLATPARP: A Phase II Single-Arm Trial of Niraparib in Platinum-Sensitive Castration-Resistant Prostate Cancer With DNA Repair Defects Recruiting NCT04288687 Phase 2 Niraparib Pill
36 A Randomized, Parallel Phase II Trial of Hypofractionated Proton Therapy or IMRT for Recurrent, Oligometastatic Prostate Cancer Involving Only Pelvic and/or Para-Aortic Lymph Nodes Following Primary Localized Treatment Recruiting NCT04190446 Phase 2
37 Fluciclovine (FACBC) PET/CT Site-Directed Therapy of Oligometastatic Prostate Cancer (Flu-BLAST-PC) Recruiting NCT04175431 Phase 2 Abiraterone Acetate;Prednisone
38 An Open-Label Multi-Center Phase II Study of Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy Recruiting NCT03821246 Phase 2 Atezolizumab;Tocilizumab;Etrumadenant
39 68Ga-NeoBOMB1 and 68Ga-PSMA R2 PET/MRI in the Evaluation of Patients With Biochemical Recurrence of Prostate Cancer Recruiting NCT03698370 Phase 2 Gallium Ga 68 DOTA-NeoBOMB1
40 The Effect of a Soy Bread Diet Intervention on Immune Function in Men With Prostate Cancer Recruiting NCT03654638 Phase 2
41 Hyperpolarized 13-C-Pyruvate Magnetic Resonance Spectroscopic Imaging Reproducibilty Pilot in Patients With Prostate Cancer Recruiting NCT03581500 Phase 2 Hyperpolarized Carbon C 13 Pyruvate
42 SIMCAP (Surgery in Metastatic Carcinoma of Prostate): Phase 2.5 Multi-Institution Randomized Prospective Clinical Trial Evaluating the Impact of Cytoreductive Radical Prostatectomy Combined With Best Systemic Therapy on Oncologic and Quality of Life Outcomes in Men With Newly Diagnosed Metastatic Prostate Cancer Recruiting NCT03456843 Phase 2 Antiandrogen Therapy;Docetaxel
43 Interest of PET-PSMA Imaging Potentiated by Androgen Blockade in Patients With Biological Relapse or Persistent Biological Disease of a Localized Prostatic Adenocarcinoma After Initial Treatment Recruiting NCT04391556 Phase 2 Firmagon
44 Advanced PET-CT Directed Post-Prostatectomy Radiotherapy to Enhance Prostate Cancer Outcomes Recruiting NCT03762759 Phase 2 Fluciclovine F18
45 A Phase I/II Study of High-Dose-Rate Brachytherapy as Monotherapy for Prostate Cancer Recruiting NCT02346253 Phase 1, Phase 2 Bicalutamide;Leuprolide Acetate;Goserelin Acetate;Triptorelin Pamoate;Degarelix
46 Randomized Phase 2 Study: Neoadjuvant Conditioning of Prostate Cancer Tumor Microenvironment Using a Novel Chemokine-Modulating Regimen Recruiting NCT03899987 Phase 2 Aspirin;Rintatolimod
47 A Phase 2 Study of Magnetic Resonance (MR) Imaging With Hyperpolarized Pyruvate (13C) in Patients With Prostate Cancer on Active Surveillance Recruiting NCT03933670 Phase 2 Hyperpolarized Carbon C 13 Pyruvate
48 A Phase 2 Trial of Radium Ra 223 Dichloride in Combination With Androgen Deprivation Therapy and Stereotactic Body Radiation Therapy for Patients With Oligometastatic Castration Sensitive Prostate Cancer Recruiting NCT03361735 Phase 2 Leuprolide Acetate;Goserelin Acetate;Degarelix
49 Hypofractionated Focal Lesion Ablative Microboost in prostatE Cancer 2.0 Recruiting NCT04045717 Phase 2
50 Randomized Three-Arm Trial to Evaluate the Effect of Neoadjuvant Apalutamide Alone or in Combination With Abiraterone Acetate and GnRH Agonist on Enhancing Surgical Outcome of Nerve-Sparing Radical Prostatectomy in Men With High-Risk Prostate Cancer Recruiting NCT02949284 Phase 2 Abiraterone Acetate;Androgen Receptor Antagonist ARN-509;Prednisone

Search NIH Clinical Center for Suppression of Tumorigenicity 12

Genetic Tests for Suppression of Tumorigenicity 12

Anatomical Context for Suppression of Tumorigenicity 12

MalaCards organs/tissues related to Suppression of Tumorigenicity 12:

40
Prostate, Bone, Breast, Lymph Node, Thyroid, Lung, Skin

Publications for Suppression of Tumorigenicity 12

Articles related to Suppression of Tumorigenicity 12:

(show top 50) (show all 2802)
# Title Authors PMID Year
1
Tumor suppression and apoptosis of human prostate carcinoma mediated by a genetic locus within human chromosome 10pter-q11. 57 61
8637912 1996
2
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. 6
26619011 2016
3
Incidental Detection of Radiotracer Uptake in Intracranial Dermoid Cyst on 18F-Prostate-Specific Membrane Antigen PET/CT During Staging for Prostate Carcinoma. 61
33323739 2021
4
Bone Infarction Mimicking a Bone Metastasis on 18F-Prostate-Specific Membrane Antigen PET/CT. 61
33323731 2021
5
Prostate Cancer Liver Metastases Presenting as Relatively Photopenic Lesions on 18F-Fluciclovine PET/CT. 61
33208612 2021
6
DNA Promoter Methylation and ERG Regulate the Expression of CD24 in Prostate Cancer. 61
33485866 2021
7
The evolutionarily conserved long non-coding RNA LINC00261 drives neuroendocrine prostate cancer proliferation and metastasis via distinct nuclear and cytoplasmic mechanisms. 61
33793068 2021
8
Delayed 68Ga-PSMA PET/CT Image-Guided Biopsy for Low-Grade Adenocarcinoma in Benign Prostatic Hyperplasia. 61
33234940 2021
9
The prognostic value and potential subtypes of immune activity scores in three major urological cancers. 61
32853461 2021
10
Performance comparison of anti-p504s (SP116) Rabbit Monoclonal Primary Antibody vs. Monoclonal Rabbit Anti-Human AMACR clone 13H4 when duplexed with VENTANA Basal Cell Cocktail (34βE12+p63) as a diagnostic aid for prostatic adenocarcinoma using immunohistochemistry. 61
33811532 2021
11
Evaluation of margins in pelvic lymph nodes and prostate radiotherapy and the impact of bladder and rectum on prostate position. 61
33454191 2021
12
Metastatic prostate adenocarcinoma to cervical lymph nodes: an unusual diagnosis on fine-needle aspiration biopsy. 61
32950433 2021
13
Single dose high-dose-rate brachytherapy with focal dose escalation for prostate cancer: Mature results of a phase 2 clinical trial. 61
33766703 2021
14
Ornithine decarboxylase activity in prostate cancer. 61
33785708 2021
15
Development of a Deep Learning Algorithm for the Histopathologic Diagnosis and Gleason Grading of Prostate Cancer Biopsies: A Pilot Study. 61
31767543 2021
16
Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer. 61
33785741 2021
17
Synthesis and anticancer activities of some new coumarin derivatives including the triazole ring and their in silico molecular docking studies. 61
33146895 2021
18
Discovery of JNJ-63576253, a next-generation androgen receptor antagonist active against wild-type and clinically-relevant ligand binding domain mutations in mCRPC. 61
33649102 2021
19
Is Retzius-sparing robot-assisted laparoscopic radical prostatectomy effective in early continence? A single-center experience of the first 50 patients. 61
33226325 2021
20
An unusual case of oedematous prostate volumetric changes observed over the course of radiotherapy on the MR linear accelerator. 61
33342695 2021
21
Galectin-3 inhibition with belapectin combined with anti-OX40 therapy reprograms the tumor microenvironment to favor anti-tumor immunity. 61
33717655 2021
22
A Novel 4H-Chromen-4-One Derivative from Marine Streptomyces ovatisporus S4702T as Potential Antibacterial and Anti-Cancer Agent. 61
33719978 2021
23
Development of a technique for evaluating the presence of malignant cells in prostatic fluid during robotic prostatectomy. 61
32868191 2021
24
Computational analysis of fused co-expression networks for the identification of candidate cancer gene biomarkers. 61
33712625 2021
25
Computerized Tomography-Guided Core-Needle Biopsy of Orbital Space-Occupying Lesions: A Case Series. 61
33796518 2021
26
Oncologic Outcomes of Radical Prostatectomy and High-Dose Intensity-Modulated Radiotherapy with Androgen-Deprivation Therapy for Relatively Young Patients with Unfavorable Intermediate-Risk Prostate Adenocarcinoma. 61
33806181 2021
27
Mining The Cancer Genome Atlas gene expression data for lineage markers in distinguishing bladder urothelial carcinoma and prostate adenocarcinoma. 61
33762601 2021
28
Neuroendocrine prostate cancer has distinctive, non-prostatic HOX code that is represented by the loss of HOXB13 expression. 61
33531604 2021
29
Identification of tumors with NRG1 rearrangement, including a novel putative pathogenic UNC5D-NRG1 gene fusion in prostate cancer by data-drilling a de-identified tumor database. 61
33583086 2021
30
Transdermal oestradiol for androgen suppression in prostate cancer: long-term cardiovascular outcomes from the randomised Prostate Adenocarcinoma Transcutaneous Hormone (PATCH) trial programme. 61
33581820 2021
31
A Pooled Toxicity Analysis of Moderately Hypofractionated Proton Beam Therapy and Intensity Modulated Radiation Therapy in Early-Stage Prostate Cancer Patients. 61
33539968 2021
32
The Stage at Presentation and Oncologic Outcomes for Agent Orange Exposed and Non-Exposed United States Veterans Diagnosed With Prostate Cancer. 61
33731274 2021
33
Grading Evolution and Contemporary Prognostic Biomarkers of Clinically Significant Prostate Cancer. 61
33562508 2021
34
Evaluation of 68Ga-PSMA PET/CT with volumetric parameters for staging of prostate cancer patients. 61
33560717 2021
35
Disparities in Refusal of Locoregional Treatment for Prostate Adenocarcinoma. 61
33630666 2021
36
[Grading of prostate adenocarcinoma: the 2019 International Society of Urological Pathology consensus]. 61
33535319 2021
37
Prostate adenocarcinoma and COVID-19: The possible impacts of TMPRSS2 expressions in susceptibility to SARS-CoV-2. 61
33609069 2021
38
Ductal Prostate Cancers Demonstrate Poor Outcomes with Conventional Therapies. 61
33279304 2021
39
Peritricuspid annular prostate pellet. 61
33574044 2021
40
Quinoline-sulfamoyl carbamates/sulfamide derivatives: Synthesis, cytotoxicity, carbonic anhydrase activity, and molecular modelling studies. 61
33684713 2021
41
Cytotoxic Fractions from Hechtia glomerata Extracts and p-Coumaric Acid as MAPK Inhibitors. 61
33669666 2021
42
Cytotoxic Physalins from Aeroponically Grown Physalis acutifolia. 61
33586438 2021
43
18F-Fluciclovine-Avid Mediastinal Lymph Node Metastasis of Cutaneous Malignant Melanoma. 61
33031240 2021
44
Cashew apple (Anacardium occidentale L.) extract from a by-product of juice processing: assessment of its toxicity, antiproliferative and antimicrobial activities. 61
33568870 2021
45
Early outcomes of single-port robot-assisted radical prostatectomy: lessons learned from the learning-curve experience. 61
32623822 2021
46
PVT1 signals an androgen-dependent transcriptional repression program in prostate cancer cells and a set of the repressed genes predicts high-risk tumors. 61
33430890 2021
47
Post-transcriptional Gene Regulation by MicroRNA-194 Promotes Neuroendocrine Transdifferentiation in Prostate Cancer. 61
33406413 2021
48
Duodenal Adenocarcinoma Mimicking Metastasis of Prostate Cancer on 18F-Prostate-Specific Membrane Antigen-1007 PET/CT. 61
33208620 2021
49
Repurposing of the Antiepileptic Drug Levetiracetam to Restrain Neuroendocrine Prostate Cancer and Inhibit Mast Cell Support to Adenocarcinoma. 61
33737929 2021
50
Clinical and Biological Features of Neuroendocrine Prostate Cancer. 61
33433737 2021

Variations for Suppression of Tumorigenicity 12

ClinVar genetic disease variations for Suppression of Tumorigenicity 12:

6 (show top 50) (show all 186)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 SPOP NM_001007228.2(SPOP):c.260A>C (p.Tyr87Ser) SNV Likely pathogenic 376553 rs1057519971 GRCh37: 17:47696688-47696688
GRCh38: 17:49619326-49619326
2 SPOP NM_001007228.2(SPOP):c.391T>A (p.Trp131Arg) SNV Likely pathogenic 376551 rs1057519968 GRCh37: 17:47696432-47696432
GRCh38: 17:49619070-49619070
3 SPOP NM_001007228.2(SPOP):c.306C>G (p.Phe102Leu) SNV Likely pathogenic 376544 rs1057519965 GRCh37: 17:47696642-47696642
GRCh38: 17:49619280-49619280
4 SPOP NM_001007228.2(SPOP):c.392G>C (p.Trp131Ser) SNV Likely pathogenic 376550 rs1057519969 GRCh37: 17:47696431-47696431
GRCh38: 17:49619069-49619069
5 SPOP NM_001007228.2(SPOP):c.398T>G (p.Phe133Cys) SNV Likely pathogenic 376546 rs1057519967 GRCh37: 17:47696425-47696425
GRCh38: 17:49619063-49619063
6 SPOP NM_001007228.2(SPOP):c.259T>A (p.Tyr87Asn) SNV Likely pathogenic 376554 rs1057519972 GRCh37: 17:47696689-47696689
GRCh38: 17:49619327-49619327
7 SPOP NM_001007228.2(SPOP):c.393G>T (p.Trp131Cys) SNV Likely pathogenic 376552 rs1057519970 GRCh37: 17:47696430-47696430
GRCh38: 17:49619068-49619068
8 SPOP NM_001007228.2(SPOP):c.304T>G (p.Phe102Val) SNV Likely pathogenic 376543 rs1057519964 GRCh37: 17:47696644-47696644
GRCh38: 17:49619282-49619282
9 SPOP NM_001007228.2(SPOP):c.398T>C (p.Phe133Ser) SNV Likely pathogenic 376547 rs1057519967 GRCh37: 17:47696425-47696425
GRCh38: 17:49619063-49619063
10 SPOP NM_001007228.2(SPOP):c.391T>G (p.Trp131Gly) SNV Likely pathogenic 376549 rs1057519968 GRCh37: 17:47696432-47696432
GRCh38: 17:49619070-49619070
11 SPOP NM_001007228.2(SPOP):c.260A>G (p.Tyr87Cys) SNV Likely pathogenic 376555 rs1057519971 GRCh37: 17:47696688-47696688
GRCh38: 17:49619326-49619326
12 CNOT9 NM_005444.3(CNOT9):c.260C>G (p.Ser87Cys) SNV Likely pathogenic 376527 rs1057519957 GRCh37: 2:219447749-219447749
GRCh38: 2:218583026-218583026
13 ERBB2 NM_004448.3(ERBB2):c.2033G>A (p.Arg678Gln) SNV Likely pathogenic 376344 rs1057519862 GRCh37: 17:37879658-37879658
GRCh38: 17:39723405-39723405
14 CNOT9 NM_005444.3(CNOT9):c.259T>C (p.Ser87Pro) SNV Likely pathogenic 376526 rs1057519956 GRCh37: 2:219447748-219447748
GRCh38: 2:218583025-218583025
15 SPOP NM_001007228.2(SPOP):c.305T>G (p.Phe102Cys) SNV Likely pathogenic 161486 rs193920894 GRCh37: 17:47696643-47696643
GRCh38: 17:49619281-49619281
16 MED12 NM_005120.3(MED12):c.3670C>G (p.Leu1224Val) SNV Likely pathogenic 376452 rs1057519912 GRCh37: X:70349258-70349258
GRCh38: X:71129408-71129408
17 SPOP NM_001007228.2(SPOP):c.397T>G (p.Phe133Val) SNV Likely pathogenic 376545 rs1057519966 GRCh37: 17:47696426-47696426
GRCh38: 17:49619064-49619064
18 TP53 NM_000546.5(TP53):c.578A>C (p.His193Pro) SNV Likely pathogenic 376612 rs786201838 GRCh37: 17:7578271-7578271
GRCh38: 17:7674953-7674953
19 CTNNB1 NM_001904.4(CTNNB1):c.98C>A (p.Ser33Tyr) SNV Likely pathogenic 17577 rs121913400 GRCh37: 3:41266101-41266101
GRCh38: 3:41224610-41224610
20 PIK3CA NM_006218.4(PIK3CA):c.1637A>C (p.Gln546Pro) SNV Likely pathogenic 375898 rs397517201 GRCh37: 3:178936095-178936095
GRCh38: 3:179218307-179218307
21 TP53 NM_000546.5(TP53):c.745A>G (p.Arg249Gly) SNV Likely pathogenic 376654 rs587782082 GRCh37: 17:7577536-7577536
GRCh38: 17:7674218-7674218
22 PIK3CA NM_006218.4(PIK3CA):c.1624G>C (p.Glu542Gln) SNV Likely pathogenic 376244 rs121913273 GRCh37: 3:178936082-178936082
GRCh38: 3:179218294-179218294
23 PTEN NM_000314.7(PTEN):c.389G>C (p.Arg130Pro) SNV Likely pathogenic 142018 rs121909229 GRCh37: 10:89692905-89692905
GRCh38: 10:87933148-87933148
24 TP53 NM_000546.5(TP53):c.658T>A (p.Tyr220Asn) SNV Likely pathogenic 376688 rs530941076 GRCh37: 17:7578191-7578191
GRCh38: 17:7674873-7674873
25 TP53 NM_000546.5(TP53):c.707A>G (p.Tyr236Cys) SNV Likely pathogenic 376693 rs730882026 GRCh37: 17:7577574-7577574
GRCh38: 17:7674256-7674256
26 AKT1 NM_005163.2(AKT1):c.49G>A (p.Glu17Lys) SNV Likely pathogenic 13983 rs121434592 GRCh37: 14:105246551-105246551
GRCh38: 14:104780214-104780214
27 TP53 NM_000546.5(TP53):c.733G>C (p.Gly245Arg) SNV Likely pathogenic 376604 rs28934575 GRCh37: 17:7577548-7577548
GRCh38: 17:7674230-7674230
28 PPP2R1A NM_014225.6(PPP2R1A):c.547C>G (p.Arg183Gly) SNV Likely pathogenic 376507 rs1057519946 GRCh37: 19:52715982-52715982
GRCh38: 19:52212729-52212729
29 BRAF NM_004333.6(BRAF):c.1790T>G (p.Leu597Arg) SNV Likely pathogenic 13968 rs121913366 GRCh37: 7:140453145-140453145
GRCh38: 7:140753345-140753345
30 CTNNB1 NM_001904.4(CTNNB1):c.94G>A (p.Asp32Asn) SNV Likely pathogenic 376228 rs28931588 GRCh37: 3:41266097-41266097
GRCh38: 3:41224606-41224606
31 TP53 NM_000546.5(TP53):c.578A>T (p.His193Leu) SNV Likely pathogenic 185822 rs786201838 GRCh37: 17:7578271-7578271
GRCh38: 17:7674953-7674953
32 TP53 NM_000546.5(TP53):c.820G>C (p.Val274Leu) SNV Likely pathogenic 376678 rs1057520005 GRCh37: 17:7577118-7577118
GRCh38: 17:7673800-7673800
33 TP53 NM_000546.5(TP53):c.527G>T (p.Cys176Phe) SNV Likely pathogenic 376569 rs786202962 GRCh37: 17:7578403-7578403
GRCh38: 17:7675085-7675085
34 TP53 NM_000546.5(TP53):c.715A>G (p.Asn239Asp) SNV Likely pathogenic 234036 rs876660807 GRCh37: 17:7577566-7577566
GRCh38: 17:7674248-7674248
35 IDH1 NM_001282386.1(IDH1):c.394C>A (p.Arg132Ser) SNV Likely pathogenic 375893 rs121913499 GRCh37: 2:209113113-209113113
GRCh38: 2:208248389-208248389
36 TP53 NM_000546.5(TP53):c.845G>A (p.Arg282Gln) SNV Likely pathogenic 237956 rs730882008 GRCh37: 17:7577093-7577093
GRCh38: 17:7673775-7673775
37 TP53 NM_000546.6(TP53):c.523C>T (p.Arg175Cys) SNV Likely pathogenic 245851 rs138729528 GRCh37: 17:7578407-7578407
GRCh38: 17:7675089-7675089
38 CTNNB1 NM_001904.4(CTNNB1):c.97T>A (p.Ser33Thr) SNV Likely pathogenic 376393 rs1057519886 GRCh37: 3:41266100-41266100
GRCh38: 3:41224609-41224609
39 TP53 NM_000546.5(TP53):c.743G>C (p.Arg248Pro) SNV Likely pathogenic 237954 rs11540652 GRCh37: 17:7577538-7577538
GRCh38: 17:7674220-7674220
40 XPO1 NM_003400.4(XPO1):c.1712A>T (p.Glu571Val) SNV Likely pathogenic 376696 rs1057520010 GRCh37: 2:61719471-61719471
GRCh38: 2:61492336-61492336
41 PIK3CA NM_006218.4(PIK3CA):c.1636C>A (p.Gln546Lys) SNV Likely pathogenic 13657 rs121913286 GRCh37: 3:178936094-178936094
GRCh38: 3:179218306-179218306
42 MED12 NM_005120.3(MED12):c.3670C>T (p.Leu1224Phe) SNV Likely pathogenic 376451 rs1057519912 GRCh37: X:70349258-70349258
GRCh38: X:71129408-71129408
43 PTEN NM_001304718.2(PTEN):c.-363C>G SNV Likely pathogenic 375958 rs121909224 GRCh37: 10:89692904-89692904
GRCh38: 10:87933147-87933147
44 BRAF NM_001374258.1(BRAF):c.1526G>T (p.Gly509Val) SNV Likely pathogenic 44803 rs121913355 GRCh37: 7:140481402-140481402
GRCh38: 7:140781602-140781602
45 TP53 NM_000546.6(TP53):c.821T>G SNV Likely pathogenic 376676 rs1057520006 GRCh37: 17:7577117-7577117
GRCh38: 17:7673799-7673799
46 TP53 NM_000546.6(TP53):c.844C>T (p.Arg282Trp) SNV Likely pathogenic 12364 rs28934574 GRCh37: 17:7577094-7577094
GRCh38: 17:7673776-7673776
47 PIK3CA NM_006218.4(PIK3CA):c.1624G>A (p.Glu542Lys) SNV Likely pathogenic 31944 rs121913273 GRCh37: 3:178936082-178936082
GRCh38: 3:179218294-179218294
48 TP53 NM_000546.5(TP53):c.821T>C (p.Val274Ala) SNV Likely pathogenic 376677 rs1057520006 GRCh37: 17:7577117-7577117
GRCh38: 17:7673799-7673799
49 PIK3CA NM_006218.4(PIK3CA):c.1034A>T (p.Asn345Ile) SNV Likely pathogenic 376488 rs1057519938 GRCh37: 3:178921552-178921552
GRCh38: 3:179203764-179203764
50 TP53 NM_000546.6(TP53):c.422G>T SNV Likely pathogenic 376568 rs587781288 GRCh37: 17:7578508-7578508
GRCh38: 17:7675190-7675190

Expression for Suppression of Tumorigenicity 12

Search GEO for disease gene expression data for Suppression of Tumorigenicity 12.

Pathways for Suppression of Tumorigenicity 12

Pathways related to Suppression of Tumorigenicity 12 according to GeneCards Suite gene sharing:

(show top 50) (show all 171)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.32 XPO1 TP53 SPOP SMAD4 PTEN PPP2R1A
2
Show member pathways
14.16 TP53 PTEN PPP2R1A PIK3CA MAP2K1 IDH1
3
Show member pathways
13.97 TP53 SMAD4 PTEN PPP2R1A MAP2K1 HRAS
4
Show member pathways
13.95 XPO1 TP53 SMAD4 PTEN PPP2R1A MED12
5
Show member pathways
13.86 XPO1 SMAD4 PPP2R1A PIK3CA MAP2K1 IDH1
6
Show member pathways
13.84 XPO1 TP53 SMAD4 PPP2R1A MAP2K1 HRAS
7
Show member pathways
13.68 TP53 SMAD4 PPP2R1A PIK3CA MAP2K1 HRAS
8
Show member pathways
13.61 SMAD4 PPP2R1A PIK3CA MED12 MAP2K1 HRAS
9
Show member pathways
13.5 TP53 PPP2R1A PIK3CA MAP2K1 HRAS ERBB2
10
Show member pathways
13.41 PPP2R1A MAP2K1 HRAS ERBB2 CTNNB1 BRAF
11
Show member pathways
13.36 TP53 SMAD4 PPP2R1A PIK3CA MAP2K1 HRAS
12
Show member pathways
13.23 TP53 PTEN PPP2R1A PIK3CA ERBB2 AKT1
13
Show member pathways
13.22 TP53 PTEN PIK3CA MAP2K1 HRAS CTNNB1
14
Show member pathways
13.19 TP53 PTEN MAP2K1 HRAS BRAF AKT1
15
Show member pathways
13.13 TP53 MAP2K1 HRAS CTNNB1 BRAF AKT1
16
Show member pathways
13.13 TP53 PTEN PPP2R1A PIK3CA MAP2K1 HRAS
17
Show member pathways
13.11 TP53 PTEN PPP2R1A CNOT9 CDKN2A AKT1
18
Show member pathways
13.1 TP53 PIK3CA MAP2K1 HRAS CTNNB1 CDKN2A
19
Show member pathways
13.09 PTEN PPP2R1A MAP2K1 HRAS CTNNB1 BRAF
20
Show member pathways
13.07 PTEN PIK3CA MAP2K1 HRAS ERBB2 CTNNB1
21
Show member pathways
13.03 PTEN PIK3CA MAP2K1 HRAS ERBB2 BRAF
22
Show member pathways
13 PTEN PIK3CA MAP2K1 HRAS BRAF AKT1
23
Show member pathways
12.99 TP53 PTEN MAP2K1 HRAS ERBB2 BRAF
24
Show member pathways
12.97 PIK3CA MAP2K1 HRAS BRAF AKT1
25
Show member pathways
12.96 PPP2R1A MAP2K1 HRAS CTNNB1 BRAF AKT1
26
Show member pathways
12.93 XPO1 TP53 PIK3CA MAP2K1 AKT1
27
Show member pathways
12.93 PTEN PIK3CA MAP2K1 HRAS BRAF AKT1
28 12.92 TP53 MAP2K1 HRAS ERBB2 BRAF AKT1
29
Show member pathways
12.91 TP53 PTEN PPP2R1A PIK3CA HRAS ERBB2
30
Show member pathways
12.89 PIK3CA MAP2K1 HRAS CTNNB1 BRAF AKT1
31
Show member pathways
12.87 PIK3CA MAP2K1 HRAS CTNNB1 AKT1
32
Show member pathways
12.87 TP53 PIK3CA MAP2K1 HRAS CDKN2A AKT1
33 12.87 TP53 SMAD4 PTEN PIK3CA MAP2K1 HRAS
34
Show member pathways
12.84 TP53 PTEN PIK3CA MAP2K1 HRAS ERBB2
35
Show member pathways
12.83 TP53 PPP2R1A MAP2K1 HRAS BRAF AKT1
36
Show member pathways
12.8 MAP2K1 HRAS CDKN2A BRAF AKT1
37
Show member pathways
12.79 PIK3CA MAP2K1 HRAS BRAF AKT1
38
Show member pathways
12.78 TP53 PTEN PIK3CA MAP2K1 HRAS ERBB2
39
Show member pathways
12.76 TP53 PIK3CA HRAS ERBB2 CTNNB1 AKT1
40
Show member pathways
12.75 TP53 SMAD4 PTEN PIK3CA MAP2K1 HRAS
41
Show member pathways
12.74 PTEN PIK3CA MAP2K1 HRAS AKT1
42
Show member pathways
12.73 PTEN PIK3CA MAP2K1 HRAS AKT1
43
Show member pathways
12.72 PPP2R1A PIK3CA MAP2K1 HRAS AKT1
44 12.72 TP53 PTEN PIK3CA MAP2K1 HRAS ERBB2
45
Show member pathways
12.67 PTEN PIK3CA MAP2K1 HRAS AKT1
46
Show member pathways
12.67 TP53 PTEN PIK3CA MAP2K1 HRAS ERBB2
47
Show member pathways
12.66 PTEN PIK3CA MAP2K1 HRAS ERBB2 AKT1
48
Show member pathways
12.66 TP53 PTEN PIK3CA MAP2K1 HRAS ERBB2
49
Show member pathways
12.64 TP53 PPP2R1A PIK3CA HRAS AKT1
50
Show member pathways
12.61 PTEN PIK3CA MAP2K1 HRAS AKT1

GO Terms for Suppression of Tumorigenicity 12

Cellular components related to Suppression of Tumorigenicity 12 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleoplasm GO:0005654 10.11 XPO1 TP53 SPOP SMAD4 PTEN MED12
2 cytoplasm GO:0005737 10.06 XPO1 TP53 SPOP SMAD4 PTEN PPP2R1A
3 nucleus GO:0005634 9.89 XPO1 TP53 SPOP SMAD4 PTEN PPP2R1A
4 mitochondrion GO:0005739 9.86 TP53 PTEN PPP2R1A MAP2K1 IDH1 CDKN2A
5 protein-containing complex GO:0032991 9.8 XPO1 TP53 CTNNB1 CNOT9 CDKN2A AKT1
6 cytosol GO:0005829 9.53 XPO1 TP53 SMAD4 PTEN PPP2R1A PIK3CA

Biological processes related to Suppression of Tumorigenicity 12 according to GeneCards Suite gene sharing:

(show all 31)
# Name GO ID Score Top Affiliating Genes
1 phosphorylation GO:0016310 10.08 PIK3CA MAP2K1 ERBB2 CDKN2A BRAF AKT1
2 apoptotic process GO:0006915 10.08 TP53 PTEN PPP2R1A HRAS CDKN2A AKT1
3 positive regulation of transcription by RNA polymerase II GO:0045944 10.06 TP53 SMAD4 MED12 KLF6 HRAS CTNNB1
4 positive regulation of apoptotic process GO:0043065 9.99 TP53 PTEN CTNNB1 CDKN2A AKT1
5 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.93 PTEN MAP2K1 HRAS BRAF
6 regulation of cell proliferation GO:0042127 9.92 TP53 SMAD4 CTNNB1 BRAF
7 negative regulation of gene expression GO:0010629 9.91 TP53 MAP2K1 HRAS CTNNB1 AKT1
8 negative regulation of cell proliferation GO:0008285 9.91 TP53 SMAD4 PTEN MAP2K1 HRAS CTNNB1
9 Ras protein signal transduction GO:0007265 9.82 TP53 HRAS CDKN2A
10 canonical Wnt signaling pathway GO:0060070 9.8 PTEN MED12 CTNNB1
11 cell cycle arrest GO:0007050 9.8 TP53 MAP2K1 HRAS CDKN2A
12 heart development GO:0007507 9.8 TP53 PTEN MED12 MAP2K1 ERBB2 CTNNB1
13 cellular response to growth factor stimulus GO:0071363 9.79 ERBB2 CTNNB1 AKT1
14 negative regulation of cell growth GO:0030308 9.78 TP53 SMAD4 PPP2R1A CDKN2A
15 epidermal growth factor receptor signaling pathway GO:0007173 9.76 PIK3CA BRAF AKT1
16 thymus development GO:0048538 9.74 MAP2K1 CTNNB1 BRAF
17 embryonic organ development GO:0048568 9.72 TP53 MED12 CTNNB1
18 cellular response to nerve growth factor stimulus GO:1990090 9.71 PTEN BRAF AKT1
19 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.71 PIK3CA CNOT9 BRAF AKT1
20 protein kinase B signaling GO:0043491 9.7 PTEN PIK3CA AKT1
21 anoikis GO:0043276 9.65 PIK3CA AKT1
22 negative regulation of cell size GO:0045792 9.65 PTEN AKT1
23 regulation of protein export from nucleus GO:0046825 9.64 XPO1 CDKN2A
24 trachea formation GO:0060440 9.61 MAP2K1 CTNNB1
25 cellular senescence GO:0090398 9.61 MAP2K1 HRAS CDKN2A
26 positive regulation of transcription, DNA-templated GO:0045893 9.61 TP53 SMAD4 MED12 MAP2K1 KLF6 CTNNB1
27 negative regulation of immature T cell proliferation in thymus GO:0033088 9.58 ERBB2 CDKN2A
28 cellular response to decreased oxygen levels GO:0036294 9.56 PTEN AKT1
29 phosphatidylinositol 3-kinase signaling GO:0014065 9.46 PTEN PIK3CA ERBB2 AKT1
30 regulation of axon regeneration GO:0048679 9.43 PTEN MAP2K1 BRAF
31 positive regulation of gene expression GO:0010628 9.28 TP53 PTEN MAP2K1 HRAS ERBB2 CTNNB1

Molecular functions related to Suppression of Tumorigenicity 12 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.96 XPO1 TP53 SPOP SMAD4 PTEN PPP2R1A
2 protein kinase binding GO:0019901 9.8 TP53 PTEN CTNNB1 CDKN2A AKT1
3 kinase activity GO:0016301 9.73 PIK3CA MAP2K1 ERBB2 CDKN2A BRAF AKT1
4 RNA polymerase II transcription factor binding GO:0001085 9.5 TP53 SMAD4 CTNNB1
5 MDM2/MDM4 family protein binding GO:0097371 9.37 TP53 CDKN2A
6 disordered domain specific binding GO:0097718 9.33 TP53 CTNNB1 CDKN2A
7 protein C-terminus binding GO:0008022 9.02 MED12 MAP2K1 HRAS ERBB2 CTNNB1

Sources for Suppression of Tumorigenicity 12

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....